Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 3831 vs Olanzapine Insulin Sensitivity Study
NCT02922426Phase 1Completed
- Sponsor
- Alkermes
- Start
- Sep 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of samidorphan in schizophrenia and bipolar disorder (BD) (3 arms), sponsored by Alkermes. Primary endpoint: Changes in blood glucose concentrations at 21 days. Started Sep 2016; status: completed.
02
Drugs
samidorphan
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT02922426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922426.